These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12825933

  • 1. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold.
    Kissau L, Stahl P, Mazitschek R, Giannis A, Waldmann H.
    J Med Chem; 2003 Jul 03; 46(14):2917-31. PubMed ID: 12825933
    [Abstract] [Full Text] [Related]

  • 2. Traceless solid-phase synthesis of 2-aminothiazoles: receptor tyrosine kinase inhibitors with dual selectivity for Tie-2 and VEGFR-2.
    Stieber F, Mazitschek R, Soric N, Giannis A, Waldmann H.
    Angew Chem Int Ed Engl; 2002 Dec 16; 41(24):4757-61. PubMed ID: 12481350
    [No Abstract] [Full Text] [Related]

  • 3. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
    Wissner A, Floyd MB, Johnson BD, Fraser H, Ingalls C, Nittoli T, Dushin RG, Discafani C, Nilakantan R, Marini J, Ravi M, Cheung K, Tan X, Musto S, Annable T, Siegel MM, Loganzo F.
    J Med Chem; 2005 Dec 01; 48(24):7560-81. PubMed ID: 16302797
    [Abstract] [Full Text] [Related]

  • 4. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor.
    Hodous BL, Geuns-Meyer SD, Hughes PE, Albrecht BK, Bellon S, Bready J, Caenepeel S, Cee VJ, Chaffee SC, Coxon A, Emery M, Fretland J, Gallant P, Gu Y, Hoffman D, Johnson RE, Kendall R, Kim JL, Long AM, Morrison M, Olivieri PR, Patel VF, Polverino A, Rose P, Tempest P, Wang L, Whittington DA, Zhao H.
    J Med Chem; 2007 Feb 22; 50(4):611-26. PubMed ID: 17253678
    [Abstract] [Full Text] [Related]

  • 5. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases.
    Singh J, Dobrusin EM, Fry DW, Haske T, Whitty A, McNamara DJ.
    J Med Chem; 1997 Mar 28; 40(7):1130-5. PubMed ID: 9089334
    [Abstract] [Full Text] [Related]

  • 6. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2, and VEGFR-3 inhibitors.
    Stahl P, Kissau L, Mazitschek R, Giannis A, Waldmann H.
    Angew Chem Int Ed Engl; 2002 Apr 02; 41(7):1174-8. PubMed ID: 12491250
    [No Abstract] [Full Text] [Related]

  • 7. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH, Wang A, Emanuel S, Deangelis A, Zhang R, Connolly PJ, Murray WV, Gruninger RH, Sechler J, Fuentes-Pesquera A, Johnson D, Middleton SA, Jolliffe L, Chen X.
    J Med Chem; 2005 Mar 24; 48(6):1886-900. PubMed ID: 15771433
    [Abstract] [Full Text] [Related]

  • 10. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE, Reddy DR, Iqbal MA, Singh J, Aimone LD, Angeles TS, Albom M, Yang S, Ator MA, Meyer SL, Robinson C, Ruggeri BA, Dionne CA, Vaught JL, Mallamo JP, Hudkins RL.
    J Med Chem; 2003 Dec 04; 46(25):5375-88. PubMed ID: 14640546
    [Abstract] [Full Text] [Related]

  • 11. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
    Zhao G, Peery RB, Yingling JM.
    Anal Biochem; 2007 Jan 15; 360(2):196-206. PubMed ID: 17141171
    [Abstract] [Full Text] [Related]

  • 12. Receptor tyrosine kinase inhibitors as anti-angiogenic agents.
    Kim DW, Lu B, Hallahan DE.
    Curr Opin Investig Drugs; 2004 Jun 15; 5(6):597-604. PubMed ID: 15242247
    [Abstract] [Full Text] [Related]

  • 13. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors.
    Renhowe PA, Pecchi S, Shafer CM, Machajewski TD, Jazan EM, Taylor C, Antonios-McCrea W, McBride CM, Frazier K, Wiesmann M, Lapointe GR, Feucht PH, Warne RL, Heise CC, Menezes D, Aardalen K, Ye H, He M, Le V, Vora J, Jansen JM, Wernette-Hammond ME, Harris AL.
    J Med Chem; 2009 Jan 22; 52(2):278-92. PubMed ID: 19113866
    [Abstract] [Full Text] [Related]

  • 14. A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity.
    Stratowa C, Baum A, Castañon MJ, Dahmann G, Himmelsbach F, Himmler A, Loeber G, Metz T, Schnitzer R, Solca F, Spevak W, Tontsch U, von Rüden T.
    Anticancer Drug Des; 1999 Oct 22; 14(5):393-402. PubMed ID: 10766294
    [Abstract] [Full Text] [Related]

  • 15. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors.
    Hasegawa M, Nishigaki N, Washio Y, Kano K, Harris PA, Sato H, Mori I, West RI, Shibahara M, Toyoda H, Wang L, Nolte RT, Veal JM, Cheung M.
    J Med Chem; 2007 Sep 06; 50(18):4453-70. PubMed ID: 17676829
    [Abstract] [Full Text] [Related]

  • 16. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
    Usui T, Ban HS, Kawada J, Hirokawa T, Nakamura H.
    Bioorg Med Chem Lett; 2008 Jan 01; 18(1):285-8. PubMed ID: 17983745
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
    Du J, Lei B, Qin J, Liu H, Yao X.
    J Mol Graph Model; 2009 Jan 01; 27(5):642-54. PubMed ID: 19081278
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.